Daclizumab induction in solid organ transplantation

Anne M. Wiland, Benjamin Philosophe

Research output: Contribution to journalReview articlepeer-review


Antibody induction therapy is used in solid organ transplantation to prevent rejection in the early postoperative period. It is especially useful in high-risk groups such as retransplants, patients with delayed graft function to delay the initiation of nephrotoxic calcineurin inhibitors (tacrolimus, cyclosporin), highly sensitised recipients and African-American recipients. Historically, antibody induction has been associated with a high incidence of adverse effects and a complicated administration regimen. Daclizumab is a monoclonal antibody that exerts its effect by binding to the alpha subunit (CD25) of the human interleukin (IL)-2 receptor on the surface of activated lymphocytes, thus preventing the binding of IL-2. It is used for induction therapy and is well-tolerated with easy administration. Although originally studied as a five-dose regimen, there is a growing accumulation of data that fewer doses (two or three) are efficacious and less costly for preventing rejection.

Original languageEnglish (US)
Pages (from-to)729-740
Number of pages12
JournalExpert Opinion on Biological Therapy
Issue number5
StatePublished - May 2004
Externally publishedYes


  • Antibody
  • Daclizumab
  • Heart
  • Induction therapy
  • Kidney
  • Liver
  • Lung
  • Pancreas
  • Transplantation

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry


Dive into the research topics of 'Daclizumab induction in solid organ transplantation'. Together they form a unique fingerprint.

Cite this